ArticlemedRxiv : the preprint server for health sciences2025
Prognostic Significance of CD8 T-cell Spatial Biomarkers in ER+ and ER- Breast Cancer.
Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Updated by
Authors and funding
10 authors.
Funding
Abstract
Tumor Infiltrating Lymphocytes (TILs) have been shown to be prognostic in Triple-Negative Breast Cancer (TNBC), but are rarely considered in other subtypes, particularly estrogen receptor (ER) positive cancers (70-80% of breast cancers), due to lower TIL counts. However, the spatial proximity of lower abundance TILs has not been evaluated in relation to breast cancer prognosis. In this study, multiplex immunofluorescent-stained images were used to identify cell types based on cytokeratin (Ck), CD8, and FoxP3 expression. Using distance-based visual morphometry between epithelial and immune cells, we computed new metrics,
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.